| Cat.No. | Name | Information |
|---|---|---|
| M54624 | DHODH-IN-4 | DHODH-IN-4 is a dihydroorotic acid dehydrogenase (DHODH) inhibitor of human and Plasmodium falciparum, with IC50 values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively.DHODH-IN-4 exhibits anti-malarial activity. |
| M54623 | DHODH-IN-15 | DHODH-IN-15 is a Hydroxyfurazan analog of A771726 and a dihydroorotic acid dehydrogenase (DHODH) inhibitor with an IC50 of 11 μM for rat liver DHODH.DHODH-IN-15 may be useful for rheumatoid arthritis related studies. |
| M54622 | hDHODH-IN-7 | hDHODH-IN-7 is a human dihydroorotic acid dehydrogenase (DHODH) inhibitor with concomitant antiviral activity and a pMIC50 of 7.4. |
| M54619 | hDHODH-IN-3 | hDHODH-IN-3 is a human dihydroorotic acid dehydrogenase (HsDHODH) inhibitor that inhibits measles virus replication with a pMIC50 value of 8.6. |
| M54618 | DHODH-IN-1 | DHODH-IN-1 is a potent dihydroorotic acid dehydrogenase (DHODH) inhibitor with an IC50 of 25 nM. In addition, DHODH-IN-1 is an inhibitor of the pyrimidine biosynthetic pathway. |
| M54617 | Laflunimus | Laflunimus is an analog of the active metabolite of Leflunomide, A771726, and an orally active inhibitor of dihydroorotic acid dehydrogenase (DHODH) and prostaglandin endoperoxide synthase (PGHS). In addition, Laflunimus inhibits immunoglobulin (Ig) secretion with IC50 values of 2.5 and 2 μM for Ig M and IgG secretion, respectively. |
| M54616 | DHODH-IN-17 | DHODH-IN-17 is a 2-anilinoylnicotinic acid and an inhibitor of human dihydroorotic acid dehydrogenase (DHODH) (IC50=0.40 μM).DHODH-IN-17 can be used in studies related to acute myeloid leukemia (AML). |
| M54615 | CHIKV-IN-2 | CHIKV-IN-2 is a potent inhibitor of chikungunya virus (CHIKV) with excellent cellular antiviral activity (EC90=270 nM) and improved liver microsomal stability. In addition, CHIKV-IN-2 exhibits inhibitory activity against dihydroorotic acid dehydrogenase (DHODH). |
| M54614 | hDHODH-IN-4 | hDHODH-IN-4 is a potent inhibitor of human dihydroorotic acid dehydrogenase (DHODH) with a pIC50 of 7.8 for inhibition of human recombinant DHODH. hDHODH-IN-4 inhibits measles virus replication with a pMIC50 of 8.8. hDHODH-IN-4 is a potent inhibitor of human recombinant DHODH. |
| M54613 | DHODH-IN-16 | DHODH-IN-16 is a potent dihydroorotic acid dehydrogenase (DHODH) inhibitor with an IC50 of 0.396 nM for human DHODH. |
| M54612 | hDHODH-IN-13 | hDHODH-IN-13 is an inhibitor of human dihydroorotic acid dehydrogenase (hDHODH) with an IC50 value of 173.4 nM. hDHODH-IN-13 can be used in studies related to inflammatory bowel disease (IBD). |
| M31056 | DSM705 hydrochloride | DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC50=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs. |
| M29633 | DSM502 | DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs. |
| M29149 | BRD9185 | BRD9185 is a dihydroorotic acid dehydrogenase (DHODH) inhibitor with an EC50 value of 16 nM measured in vitro. |
| M28227 | Vidofludimus hemicalcium | Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR. |
| M22180 | DSM265 | DSM265 is a long-acting inhibitor of Plasmodium falciparum dihydroorotic acid dehydrogenase (PfDHODH) with an IC50 value of 8.9 nM. In addition, DSM265 inhibits the growth of Pf3D7 with an EC50 value of 4.3 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
